MEI Pharma
Market cap, mNAV, and volume data may not accurately represent reality during the merger process.
LTC Holdings
Key Metrics
Market cap, mNAV, and volume data may not accurately represent reality during the merger process.
Market cap, mNAV, and volume data may not accurately represent reality during the merger process.
Market cap, mNAV, and volume data may not accurately represent reality during the merger process.
About MEI Pharma
MEI Pharma has pivoted its treasury strategy to focus on Litecoin (LTC), partnering with crypto trading firm GSR and even bringing Litecoin creator Charlie Lee onboard as an advisor. A $100 million private placement will fund the acquisition of LTC, making MEIP the first Nasdaq-listed company to fully align its reserves with Litecoin.
This strategy institutionalizes Litecoin as a reserve asset, citing its long history, regulatory clarity, and payment utility. MEI's pivot gives investors exposure to Litecoin performance via public equity, creating a "MicroStrategy-for-Litecoin" model and opening the door for more altcoin-based treasury plays in corporate America.
As of December 2025, it held 0 LTC valued at .